By Christian Viveros-FaunĂ©
By Miriam Felton-Dansky
By Tom Sellar
By Tom Sellar
By Jessica Dawson
By Tom Sellar
By R. C. Baker
By Tom Sellar
The Schiavo episode, of course, exposed the clout of the Christian right and the divisions within the nation. But it also highlighted the growing prominence and internal disagreements of bioethics. Confronted with such controversies and with new biotechnologies, we increasingly turn to these experts for guidance. Now, with the press abuzz about Bush's stem cell veto and post-Katrina lethal injections, bioethicists seem assured of continued status as media darlings. Bioethics is also expanding its presence in institutions outside academiain government, hospitals, and pharmaceutical companies. As its influence grows, members of the bioethics community are debating not only the field's issues, but also its proper role.
Bioethics refers to both a general area of inquiry and an interdisciplinary academic field. The field is growing fast, with numerous programs cropping up in recent years. The major center at the University of Pennsylvania was founded in 1994, and Columbia's Center for Bioethics just celebrated its fourth anniversary. Even today, most scholars in the field have degrees in other disciplines law, philosophy, medicine, theology. But as more universities offer degrees in bioethics, more graduates will share a common background, including the history and methods of bioethics. Career options include work in academia, hospitals, and industry. The elastic designation of "bioethicist" can refer to someone with a degree in the field or to anyone who studies the relevant issues.
Some of those issues are age-old doctor-patient relationships, research ethics. (There is more consensus in these areas; no bioethicist would argue against informed consent, for example.) Other questions concern biotechnological innovations such as cloning, genetic engineering, stem cell research, and organ transplantation. Perhaps because the quandaries are newer, or because the competing values involved are more complex, consensus here is not achievable, or even desired.
According to Ruth L. Fischbach, director of the bioethics center at Columbia, "There have always been ethical considerations, from the time of Hippocrates," but the modern field arose in response to the atrocious Nazi experimentation on human subjects. Others link the field's birth with the new technologies of the late 1960s and early 1970s, such as kidney transplants and advances in genetics. But whether its roots are traced to moral failure or scientific success, everyone can agree that the field aims to negotiate how to capitalize on the latter while avoiding the former.
Bioethics was never destined for sequestration in the ivory tower. The nature of the field makes it more applicable to practical affairs than, say, French literary theory. But after Georgetown founded the first academic center, the Kennedy Institute of Ethics, in 1971, some factions did adhere to fundamentally academic modes of inquiry. A central debate is whether the purpose of bioethics should be to illuminate or to advise.
Carl Elliott, professor at the University of Minnesota's Center for Bioethics, has written that "bioethics may begin to look less like a field of scholarship and more like a branch of the advice industry." "Part of the reason I don't like to be called a bioethicist," he says, "is that it's assumed that the conversation is going to be about right or wrong." He is more interested in the reasons underlying the demand for biotechnologies (e.g., enhancements) as analyzed in his 2003 book Better Than Well.
Others believe that bioethicists have the responsibility to play an advisory role. Arthur Caplan, director of U Penn's center, argues, "Illumination is a perfectly fine activity, but ultimately you have to advocate when you've reached a position you can defend." He adds, "You don't want to confuse advocacy with final authority. When people say, 'Why should I listen to what you have to say?' the answer is, 'You don't have to.' "
But bioethicists have an aura of moral authority not enjoyed by, say, politicians. Skeptics worry that bioethics will be exploited for moral cover. The President's Council on Bioethics, convened in 2001, produces reports, holds hearings, and offers nonbinding policy recommendations. The council's purview includes cloning, stem cells, and "human dignity," and its work shows impressive sensitivity. But critics charge that it "very much reflects Bush's agenda," says Yale's Robert J. Levine. In 2004, two members with dissenting views on stem cell research were replaced.
The problem is even more vexed when it comes to Big Pharma. "I'm sad to say I'm a little skeptical of bioethicists who work for pharmaceutical companies," says Fischbach. Elliott fears that as insiders, bioethicists employed by industry will inevitably become more accommodating. He describes academia as a "protected place where you can say unpopular things." Some of his colleagues, he alleges, "treat industry funding as if it's more or less equivalent to academic funding, but it's not. The agenda is making money," not intellectual inquiry. If the company doesn't like what it hears, it can find a bioethicist with a more sympathetic opinion. (Many centers get some of their funding from industry as well.)